CClinicalTrials.gg
Status unknownNCT04419285PROMAUpdated Jun 5, 2020

Mobility Protocol Adapted for Advanced Visually Impaired Subjects

An interventional study of Locomotion task and Posturology task SOT (Sensory Organization Test) in Pigmentary Retinopathy, sponsored by Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. Status unknown at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-05.

Sponsored by Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Retinitis Pigmentosa is characterized by a progressive disappearance of photoreceptors, responsible for a progressive and severe loss of vision.

People Retinitis Pigmentosa therefore encounter a large number of difficulties in daily life, specifically for:

  • Visual research
  • Visuo-motor coordination in tasks requiring fine motor control
  • Visuo-motor coordination in mobility tasks

This study aims to assess the difficulties in the daily life of subjects with Retinitis Pigmentosa at a very advanced stage unsing, quaify of life questionnaires, simplified locomotion tasks in real situation and a posture task.

They are proposing a new test adapted and carried out in real situations, in binocular and monocular vision, making it possible to finely assess locomotion especially for "very low vision" patients.

This test will also ultimately make it possible to better evaluate the effectivements, that is to say to observe and quantify objectively by a score the performance progression obtained for locomotion tasks related to the visual recovery generated by the treatment.

Read the detailed description

This is monocentric study and the total duration of the study is 48 months. The duration of participation for each research subject is 3 months and maximum 4 visits. This is research involving the human type of non-invasive interventional research, with minimal risks and constraints.

This exploratory study will be conducted on a group of patients with Retinitis Pigmentosa at a very advanced stage.

There will be an inclusion visit including a visual assessment and an ophthalmological consultation. Two experimental visits with tests carried out in a real environment including a locomotion and a posture tasks. An end-of-study visit within a maximum of 1 month following the second experimental visit.

02

Conditions studied

  • Pigmentary Retinopathy

Browse trials for

03

In context

Retinitis Pigmentosa

268 studies on the registry are indexed under Retinitis Pigmentosa; 71 are open to participants now.

This study's planned enrollment of 50 is above the median of 27 across 173 interventional studies indexed under Retinitis Pigmentosa.

Browse Retinitis Pigmentosa studies →

Lead sponsor

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts is the lead sponsor of 28 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Retinitis Pigmentosa, non-syndromic, the diagnosis of which has been confirmed by an ophtmalmologist
  • ETDRS visual acuity less than 2/10 (>+0.7 logMAR; \<20/100 Snellen)
  • Doesn't participate in clinical research that may interfere with this study
  • Sufficient knowledge of the French language to ensure a perfect understanding of the tasks to be performed and the instructions received
  • Consent to the study signed after information by the investigator
  • Health insurance affiliation

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Inability to give personal consent
  • Cataract surgery in the 3 months preceding inclusion
  • Amblyopia
  • Inability to comply with the instructions for carrying out the study tasks or to complete the study visits
  • MMSE score without visual item ≤ 20/25
  • Drug treatment which can lead to motor, visual or cognitive disorders (PSA, neuroleptics,etc.) or which may interfere with the study's evaluations
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Retinitis Pigmentosa patients

    50 patients with very severe Retinitis Pigmentosa

    Behavioral: Locomotion task · Behavioral: Posturology task SOT (Sensory Organization Test) · Behavioral: The quality of life questionnaire

Interventions

  • BehavioralLocomotion task

    The locomotion task takes place on a Streetlab platform. The subject must follow a line on the ground, straight or composed of turns.

    Also known as: Streetlab platform

  • BehavioralPosturology task SOT (Sensory Organization Test)

    The task takes place on a Streetlab platform with uniform walls without decorations in order to remove any localization element.

    Also known as: Streetlab platform, Opal MobilityLab

  • BehavioralThe quality of life questionnaire

    Study the correlations between the subjects' quality of life scores and the results during behavioral tests. Identify the subjective parameters most sensitive to sensory-motor performance.

    Also known as: NEI-VFQ-25, ULV VFQ (Ultra Low Vision Visual Funnctioning Questionnaire)

06

What researchers measure

Primary outcomes

  1. Discriminating

    Study of the correlation between the severity of the impairment with regard to visual evaluations (visual acuity, visual field, ect) and the performance score for locomotion and posture tests.

    Time frame: Month 1

  2. Reproducibility

    Graphical and tabular representations will be prepared to represent the correlation between test results and visual function measures on the one hand and daily life activities on the other.

    Time frame: Month 1

  3. Validity of construction

    Graphical and tabular representations will be prepared to represent the correlation between test results and visual function measures on the one hand and daily life activities on the other.

    Time frame: Month 1

Secondary outcomes

  1. Measurement of postural parameters

    The locomotion task which takes place in a Streetlab platform. The subject must follow a line on the ground, straight or composed of turns. For the other tests, the number of turns and the distance to be covered are identical, but the shapes of the courses are systematically different. The posturology task SOT (Sensory Organization Test) takes place in a StreetLab platform with uniform walls without decorations so as to remove any localization element. The subject is instructed to stand with his hands on his hips as steadily as possible. This test includes 4 experimental conditions for disturbing sensory inputs. the duration of acquisition is 30 seconds, during which the subject must hold a standing position as tatic as possible, without speaking, els hands positioned on the hips while looking straight ahead. Four experimental conditions are tested: Eyes open on a hard floor, eyes closed on a hard floor, eyes open on a foam tray, eyes closed on a foam tray.

    Time frame: Month 1

07

Study locations

1 of 1 sites recruiting
  • Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
    Paris, 75012, France
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04419285
Lead sponsor
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Responsible party
Sponsor
First posted
Jun 5, 2020
Start date
Mar 2, 2020
Primary completion
Jun 2, 2024 (estimated)
Completion
Jun 4, 2024 (estimated)
Last update
Jun 5, 2020

Study contacts

Tania TR RILCY
Contact
trilcy@15-20.fr
+33140021126
Hayet HS SERHANE
Contact
hserhane@15-20.fr
+3314021144
Saddek SM MOHAND-SAID, MD
principal investigator · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion